Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

BACKGROUND: Previous human clinical trials of insulin-like growth factor type I (IGF-1) in amyotrophic lateral sclerosis (ALS) have been inconsistent. This phase III, randomized, double-blind, placebo-controlled study was undertaken to address whether IGF-1 benefited patients with ALS. METHODS: A to...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Sorenson, E J., Windbank, A J., Mandrekar, J N., Bamlet, W R., Appel, S H., Armon, C, Barkhaus, P E., Bosch, P, Boylan, K, David, W S., Feldman, E, Glass, J, Gutmann, L, Katz, J, King, W, Luciano, C A., McCluskey, L F., Nash, S, Newman, D S., Pascuzzi, R M., Pioro, E, Sams, L J., Scelsa, S, Simpson, E P., Subramony, S H., Tiryaki, E, Thornton, C A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Academy of Neurology 2008
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2617770/
https://ncbi.nlm.nih.gov/pubmed/19029516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/01.wnl.0000335970.78664.36
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky